Pro-angiogenic factors play a crucial role in the treatment of malignant tumors, particularly in anti-angiogenic therapies. This study evaluated vascular and lymphatic adverse events (AEs) associated with four anti-tumor angiogenesis drugs in the WHO-VigiAccess database. It also compared the adverse drug reaction (ADR) profiles of these drugs to support personalized treatment decisions and optimize therapeutic benefits and safety.